
Shares of Novavax (NASDAQ:NVAX) fell 26.2% on Jul 14, after the European Medicines Agency's (TSE: EMA) Pharmacovigilance Risk Assessment Committee ("PRAC") updated the product label of Nuvaxovid, the company's COVID-19 vaccine, to include some potential side effects like severe allergic reactions and skin problems.
Nuvaxovid is currently authorized in the European Union for use in individuals aged 12 years and older.